🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10 results for “rilzabrutinib” Clear

  1. A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 other active

    1 trial

  2. Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  3. Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.

    Pharma Mar S.A.

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  4. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Autoimmune haemolytic anaemia

    phase 3 small molecule active

    1 trial

  5. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Blood and lymphatic diseases

    phase 3 small molecule active

    1 trial

  6. A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 2 other active

    1 trial

  7. Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Warm autoimmune hemolytic anemia

    phase 2 small molecule active

    1 trial

  8. Rilzabrutinib

    Pharma Mar S.A.

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  9. Rilzabrutinib, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 2 small molecule active

    1 trial

  10. A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants

    Sanofi Pharma Bristol-Myers Squibb

    Immune Thrombocytopenia Purpura

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources